Stem Cell Stocks

[sweet crude]

SVFCE stem cell treatment play

SVFCE is one of the few "FDA compliant" stem cell treatment companies in the US. Located in Manhattan, NYC SVFCE treatment center positions SVFCE to attract players from such stocks as ACTC CYPX ASTM STEM

[Hedge Starz]

$VSTA - VistaGen Therapeutics is a MUST WATCH here on a Chart Breakout past $.80. The float is 1.1M (OS of ~20MIL) and HUGE Releases in the past month - http://finance.yahoo.com/q?s=vsta&ql=1
http://www.otcmarkets.com/stock/VSTA/company-info
CHART - http://stockcharts.com/h-sc/ui?s=VSTA&p=D&b=5&g=0&id=p91266256222
BOARDMARK it Here - http://investorshub.advfn.com/VistaGen-Therapeutics-Inc-VSTA-22070/

$2 Price target with current market price of $.85 - Accum/RSI/MACD all bullish

[DFLY]

will do thanks

[Pyckstocks]

$VSTA I agree with you my friend. The least little push and we head over $1 imo

[Hedge Starz]

You should add $VSTA to your list even though this board is silent

[X27RAY]

ACTC.ob receives FDA approval
company http://www.forbes.com/feeds/ap/2010/11/22/science-health-care-us-sci-stem-cell-blindness_8155615.html

[califax]

2010 Stem Cell Summit

The 5th Annual Stem Cell Summit will convene in New York on February 16.



Agenda
http://www.stemcellsummit.com/agenda.html

[califax]

World Stem Cells & Regenerative Medicine Congress 2010



http://www.terrapinn.com/2010/stemcells/

[califax]

Cord blood stem cell transplant hopes lifted

Monday, 18 January 2010
http://news.bbc.co.uk/2/hi/health/8462488.stm

A technique which may eventually remove the need for matched bone marrow transplants has been used in humans for the first time.

It is hoped that "master cells" taken from umbilical cords could be used on any patient without rejection.

The latest advance, published in the journal Nature Medicine, greatly multiplies the tiny number of cells from the cord ready for a transplant.

UK charity Leukaemia Research said this could be the "holy grail" for doctors.

Aggressive treatment

The current system of bone marrow transplantation helps patients who have diseases, such as leukaemia, which affect the stem cells in their bone marrow where new blood cells are grown.

Their own bone marrow cells are killed off by aggressive treatment and cells from a matched donor are introduced in their place.

However, a matching donor cannot always be found, despite extensive donor registries held by organisations such as the Anthony Nolan Bone Marrow Trust and, even with a carefully matched donor, there is still a risk that the patient's body will reject the new cells.

Cells extracted from umbilical cords could overcome these problems - they do not have the characteristics which would normally trigger immune rejection, so it is likely that cells from a single baby's cord could be used in any patient, without the need for matching.

However, there is one big disadvantage - there are not enough cells in a single cord to meet the needs of an adult patient.

Scientists have been looking for ways to either combine the cells from more than one baby, or to "expand" the cell numbers in the laboratory.

The second of these options is far from straightforward - simply allowing the stem cells to divide and increase in the laboratory means that many of the resulting extra cells will be simple blood cells, which do not have the ability to produce new cells themselves.

Quick to work

Researchers at the Fred Hutchinson Cancer Research Center in Seattle believe they may have found a way.

They manipulated a "signalling pathway" in the stem cells to trigger an increase in numbers without losing their stem cell status.

After success in laboratory animals, these cells were used in human patients, and the researchers found that they were accepted by the body more quickly and contributed more to the rebuilding of functioning bone marrow than "non-expanded" cord blood transplants.

Dr David Grant, Scientific Director of charity Leukaemia Research said: "The holy grail is to have an 'off the peg' source of unlimited numbers of 'neutral' stem cells which can be given to any patient safe in the knowledge that they will not cause the very difficult 'graft versus host' problems that lead to rejection and often the death of the patient.

"This is a promising development towards this because the concern has been that once stem cells start 'growing' they lose their stem cell properties and progress to ordinary blood cells with a very limited lifespan."

Henny Braund, chief executive of The Anthony Nolan Trust, said the potential for umbilical cord blood was "huge", and that the charity had already imported well over 250 units of umbilical cord blood.

"Sadly in the UK, despite our scientific expertise, umbilical cord blood is still very much an untapped resource and we are only able to collect and store a tiny amount of the cords we need.

"We really need a properly resourced UK cord blood collection programme.

"Further investment is crucial if we are to capitalise on this amazing resource and save more lives."

[califax]

SCLL - Current report filing (8-K)

Date : 01/13/2010 @ 3:00PM
Source : Edgar (US Regulatory)
Stock : - (SCLL)

http://ih.advfn.com/p.php?pid=nmona&cb=1263413430&article=41095210&symbol=NO^SCLL

Stem Cell Innovations, Inc., (SCLL.PK) wishes to update its shareholders on various aspects of the company over the past year.

Our human embryonic germ cell technology has matured substantially. This work was significantly more difficult than originally anticipated but has resulted in a series of interesting and useful observations that will fill in several missing pieces in human stem cell biology. These observations are currently being finalized and assembled into a form suitable for publication in scientific journals. We anticipate the publication of several such scientific papers over the coming year and these advances will enable us to pursue the application of our technology to drug discovery, liver disease and cancer. It is important to note that this technology is completely separate from standard human embryonic stem cells and comprises a unique and valuable intellectual property.

As a result of the shareholder vote that was held in August, the number of authorized shares was expanded to 20 billion. There are currently 2,844,387,312 shares issued and outstanding. The financing by Margie Chassman that was announced in conjunction with the vote has been completed. These funds, along with income from ongoing and new contract research, should enable the Company to put a program in place over the next six to nine months that will enable us to become listed again on the Bulletin Board and become current with our filings. It is important to the Company to be as transparent as possible within the confines of this difficult financial environment and we are working diligently to achieve this.

[califax]

LINK back to currently Stem Cell MOMO play!?

[califax]

SCLL -

[up-down]

U.S. set to fund more stem cell study
NEW LINES APPROVED
'Today's announcement is the first wave'

by Rob Stein
Washington Post Staff Writer
Thursday, December 3, 2009

The Obama administration has begun approving new lines of human embryonic stem cells that are eligible for federally funded experiments, opening the way for millions of taxpayer dollars to be used to conduct research that was put off-limits by President George W. Bush.

Launching a dramatic expansion of government support for one of the most promising but most contentious fields of biomedical research, the National Institutes of Health on Wednesday authorized the first 13 lines of cells under the administration's policy and was poised to approve 20 more Friday.

"This is the first down payment on what is going to be a much longer list that will empower the scientific community to explore the potential of embryonic stem cell research," said NIH Director Francis S. Collins. "Today's announcement is the first wave."

An additional 76 stem cell lines are awaiting vetting, and researchers have indicated that they plan to submit at least 254 more for approval.

The NIH has already authorized 31 grants worth about $21 million for research on human embryonic stem cells, money that was contingent on new lines passing government muster. The grants are for a variety of research, including work aimed at developing cells that could be used to treat diseases of the heart and nervous system.

Many other grant requests have been submitted by researchers hoping to use some of the $10 billion the NIH received as part of the economic stimulus, Collins said.


"We've been waiting with bated breath to get started," said George Daley, a stem cell researcher at Children's Hospital in Boston who created 11 of the lines approved Wednesday. "We could do today what we couldn't do yesterday."

Bush severely restricted federal funding for human embryonic stem cell research because of moral objections to the destruction of human embryos to obtain the cells. Federally funded scientists were limited to studying 21 existing cell lines that many criticized as flawed and inadequate; had to erect cumbersome bureaucratic procedures to separate government-funded research from privately funded work; and were sometimes prevented from sharing ideas.

Now, although embryonic stem cell lines will still have to be created using private funding, federal funding will be permitted for experiments using a much larger array of lines, once those lines have been scrutinized to make sure they were created from embryos obtained ethically. That will vastly expand the number of scientists and types of experiments using taxpayer dollars.

"This is what we've been waiting for," said Amy Comstock Rick of the Coalition for the Advancement of Medical Research, which has been leading the lobbying effort to loosen the federal restrictions. "We've very excited."

Opponents see 'tragedy'


But the announcement was condemned by opponents of the research, who argued that the work is not only unethical but unnecessary, because of the availability of adult stem cells and other more recently identified alternatives.

"Ethically, we don't think any taxpayer should have to fund research that relies on destroying early human life at any stage," said Richard M. Doerflinger of the U.S. Conference of Catholic Bishops. "But the tragedy of this is multiplied by the fact that no one can think what the problem is that can only be solved by these cells."

Collins, a geneticist and evangelical Christian whose appointment raised concern among some scientists, defended the work.

"I think that there is an argument to be made that what is being done is ethically acceptable," Collins said, "even if you believe in the inherent sanctity of the human embryo."

Many scientists believe embryonic stem cells will yield fundamental insights into the underlying causes of a host of diseases and could be used to cure diabetes, Parkinson's disease, paralysis and other ailments. But extracting the cells destroys days-old embryos. In an effort to prevent tax dollars from encouraging the destruction of more embryos, Bush on Aug. 9, 2001, restricted federal funding to studies involving lines that were already in existence.

Critics have long complained that those cells had shortcomings, such as defects that could make them dangerous to transplant into people.

In the meantime, hundreds of newer lines have been developed that offer a host of opportunities. Many, for example, carry defects for specific diseases and could yield crucial clues into how those illnesses develop and might be cured.

U.S. researchers who wanted to study them have had to use private funds and go through complicated bureaucratic hoops, sometimes essentially creating parallel laboratories with carefully segregated staff and equipment to keep federal funds from being used for the experiments.

Guidelines ordered


President Obama fulfilled a campaign promise in March by signing an executive order lifting the Bush restrictions and ordering the NIH to develop guidelines to decide which lines could be ethically used.

In a political compromise, the guidelines finalized in July limited funding to lines created from excess fertility clinic embryos, as long as they were deemed to have been obtained ethically. The lines have to meet a strict set of criteria, such as making sure couples were not offered any financial incentives, knew the embryos would be destroyed for research and were offered the option of donating them to other couples.

Some proponents of the research criticized the guidelines for not going further and allowing, for example, federal funds to be used to create embryos specifically for research purposes or by cloning techniques. Federal funds are also still barred by Congress from being used to create the cell lines.

The final NIH guidelines created an elaborate process for vetting cell lines. Those that meet the criteria set forth by the guidelines could be approved by the agency's staff, while those that are more questionable because they were obtained under less stringent requirements will be vetted individually by a special advisory committee to the NIH director.

It was unclear whether any of the 21 lines originally approved by Bush would qualify; so far only one has been submitted for review. The lines approved Wednesday -- 11 at Children's Hospital and 2 at Rockefeller University in New York -- met the basic requirements.

http://www.washingtonpost.com/wp-dyn/content/article/2009/12/02/AR2009120201955.html

[DFLY]

Stemmies waking today on news!NIH approves first batches of embryonic stem cells for tax-funded research, promises more soon
By LAURAN NEERGAARD , Associated Press

Last update: December 2, 2009 - 11:35 AM

WASHINGTON - A new era in embryonic stem cell research arrived as the government approved 13 batches of the master cells for a study using taxpayer dollars, with dozens more in the pipeline.

President Barack Obama lifted restrictions on stem cell research last spring. But $21 million worth of pending new studies couldn't begin until the National Institutes of Health determined which of hundreds of already created stem cell lines — culled from embryos left over from fertility treatments — were ethically appropriate to use.

On Wednesday, the NIH said that 13 batches are available immediately and another 96 are undergoing NIH review

[PatD100]

Cell Therapeutics March Net $1.66M >CTIC Last update: 4/30/2009 5:54:40 PM DOW JONES NEWSWIRES Cell Therapeutics Inc. (CTIC) Thursday reported a net profit of $1.66 million attributable to common shareholders in March, swinging from a net loss of $8.04 million in February. -By Denise Jia, Dow Jones Newswires; 202-862-1359; [e-mail] (END) Dow Jones NewswiresApril 30, 2009 17:54 ET (21:54 GMT

[sweet crude]

Stem Cell Treatment - Q&A

Some patients have felt "symptoms" after treatment, some even during the stem cell infusion. These seem to usually disappear. Why do they occur and then go away?

Dr. Feinerman: The question does not mention what stem cells were infused or for what condition. Patients can sometimes experience flushing and warmth to the face and body that is transient. Also muscle aches and generalized malaise may occur. All of these symptoms disappear uneventfully without any treatment.


Many patients have already had one or more stem cell treatments and have had vastly different expectations about the time frame for results. We have been told (from time of treatment): up to a year or longer; 6 months; 3-6 months; several weeks or less. Doctors and/or clinics have given us all of these time frames. What would be realistic? Would the type of stem cells have anything to do with it?

Dr. Feinerman: Improvement after stem cell treatments is relative to the nature of the disease, duration of the disease, age of patient, source and type of stem cells, and the severity of the disease in the patient.

For example, a patient with diabetes receiving pancreatic islet stem cells often will exhibit improvement within 4-6 weeks in decreasing their insulin dose, and hopefully being able to stop it after 3-6 months. Patients with Alzheimer's or spinal cord injuries may take 6-12 months before they see initial improvement.

What current research do you consider the most promising and/or what researcher's work do you most closely follow? Do you know what Phase II or Phase III trials look like they may truly lead to approved treatments the soonest?

http://www.wallstreetnewscast.com/news/stemceltreatment.html

[DFLY]

NBS news>>

NeoStem Expands Stem Cell Collection Center Network Into New Jersey Led by Leading Plastic Surgeon and Anti-Aging Authority
Mar 19, 2009 4:59:00 PM



NEW YORK, March 19 /PRNewswire-FirstCall/ -- NeoStem, Inc. (NYSE Alternext US: NBS), which is pioneering the pre-disease collection, processing and long-term storage of adult stem cells for future medical need, announced today it has signed an agreement with Dr. Vincent C. Giampapa, M.D., F.A.C.S. to open a new stem cell collection center at the Giampapa Institute for Anti-Aging Medical Therapy in Montclair, New Jersey. The agreement adds to NeoStem's national network of metropolitan stem cell collection centers, the most recent of which was in New York City. In February 2009, NeoStem announced it has licensed the exclusive worldwide rights to Dr. Giampapa's innovative stem cell technology and applications for cosmetic facial and body procedures and skin rejuvenation. Dr. Giampapa is a Board-certified plastic reconstructive surgeon and Assistant Clinical Professor of Plastic and Reconstructive Surgery at the University of Medicine and Dentistry of New Jersey. One of the first certified anti-aging medical physicians in the world, he is Director of the Plastic Surgery Center Internationale as well as The Giampapa Institute.


Dr. Giampapa is renowned for a non-surgical complete facial rejuvenation procedure that involves the use of adult stem cells. The procedure can be accomplished under local anesthesia in an office setting and requires only about a week of recovery time. He is also a founder of Suracell Inc. (www.suracell.com), which formulates for clients a personal genetic health program based on analysis of an individual's genetic profile. "We are currently performing Stem Cell Face Lifts and are looking forward to giving our patients the opportunity to have their stem cells collected today for multiple treatments in the future," said Dr. Giampapa.


NeoStem's collection centers utilize a minimally invasive proprietary system to enable health conscious consumers to donate and store their own stem cells when they are young and healthy, for personal use years or decades later in times of medical need. The Company's stem cell collection center model generates revenue for the Company through ongoing fees derived from stem cell collections and processing and fees charged to the centers for marketing and support. Long-term storage generates further revenue on a recurring basis.


Robin Smith, MD, CEO of NeoStem, said, "We are extremely pleased to have Dr. Giampapa's Institute join our network of collection centers. He is at the forefront of developing innovative stem cell therapies addressing anti-aging and regenerative medicine, an important arena for NeoStem. His prestige internationally as well as in the U.S. will draw clients from around the world, especially China, through NeoStem's relationships there. We look forward to a fruitful partnership with him on many fronts."


About NeoStem, Inc.

NeoStem is developing a network of adult stem cell collection centers that are focused on enabling people to donate and store their own (autologous) stem cells when they are young and healthy for their personal use in times for future medical need. The Company has also entered into research and development through the acquisition of a worldwide exclusive license to technology to identify and isolate VSELs (very small embryonic-like stem cells), which have been shown to have several physical characteristics that are generally found in embryonic stem cells.


In November 2008, NeoStem signed a definitive agreement to merge China Biopharmaceuticals Holdings, Inc. (OTCBB: CHBP), a Chinese pharmaceutical company with and into the Company's wholly-owned subsidiary. CHBP holds a 51% interest in Suzhou Erye Pharmaceutical Co. Ltd. ("Erye"). For the nine months ended September 30, 2008 CHBP reported revenues of $37 million representing an increase of 64% over the comparable prior period which was primarily attributable to Erye's performance. Eyre currently manufactures over 100 drugs on seven GMP lines, including small molecule drugs. In business for more than 50 years, it is highly respected for its quality, service and reliability.


Also in November 2008, NeoStem agreed to acquire a Hong Kong corporation with a series of contracts in place with Shandong New Medicine Research Institute of Integrated Traditional and Western Medicine LLC ("Shandong"). Shandong is a provider of regenerative medical therapies in China and provides a multitude of treatments including cell regenerative therapies.


The closing of the CHBP and Shandong transactions are subject to shareholder approvals and other conditions set forth in the agreements. The acquisitions will add materially to NeoStem's existing business and intellectual property platform and open international access for the Company and its clientele to advanced stem cell technologies for a growing number of conditions.


For more information, please visit: www.neostem.com.


Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. The Company's actual results, including the success of the Dr. Giampapa stem cell collection center, the successful closing of the CHBP and Shandong transaction and the realization of the potential strategic benefits of the transactions could differ materially from those anticipated in these forward-looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the "Risk Factors" described in the Company's periodic filings with the Securities and Exchange Commission. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.


Contact:
NeoStem, Inc.
Robin Smith, Chief Executive Officer
T: 212-584-4180
E: [e-mail]
www.neostem.com




SOURCE NeoStem, Inc.



----------------------------------------------
Robin Smith
Chief Executive Officer
NeoStem
Inc.
[phone]
[e-mail]

[Calc]

Research Opinion Removed for Lack of Payment

Ludlow Capital Group, Inc. has made numerous written and oral requests for payment of restricted shares payable for consultant and advisory agreement signed on August 2008, and has thus far gone unfulfilled with no response or action from Cephas Holding Corp. (CEHC)

Due to this lack of payment, and action from Company, all coverage and potential mergers candidates from Ludlow Capital Group have been cancelled or put on hold until further notice.

For more information on this issue contact.

Peter Klamka
Phone: [phone]
Email: [e-mail]

[SFGiants]

XYTS +116% today
ended at .13
106K volume

[Calc]

CEHC IS NOT acquiring anything just yet.

Here is the rest of what Ludlow said. I always like to see the whole story, as I;m sure everyone does. It is misinformation to say that CEHC is acquiring anything and that has NOT been PR;d by anyone.

"" Cephas Holdings continues in talks to acquire an operational stem cell treatment company, with the potential for a letter of intent and merger agreement within the next 15 to 30 days.

Note: Talks are preliminary and there can be no assurance that a final agreement can be agreed upon by one or both parties, and thus should be considered when reviewing this company as a potential investment.""

It's just in the TALKING stage and no one knows if the talks will lead to ANYTHING.

[DFLY]

NBS big pop into close today! Maybe somethin up?!6m big board stemmies lets see the monsta wake!

[cmg1963]

SCLL green today... nice steady climb

[Soapy Bubbles]

STEM Notes

[Carlito]

OMHI 002 x 004








Under Sigma Capital Partners portfolio http://www.sigmacp.com/html/invesment_portfolio.html ))

[PIZZABUSTER1]

OMHI-KWBT RT NOW READY FOR TAKE OFF

[swanlinbar]

Obama's end stem-cell research ban 'huge' in fight against diabetes(right up VODGE alley)
BY Bill Egbert
DAILY NEWS STAFF WRITER

Monday, March 9th 2009, 12:32 AM


Lombard for News

Danielle and Troy Gregory, and their kids Leo, 6, and Oliva, 8, on Sunday with a clown at annual Cranival for a Cure. Leo was diagnosed with diabetes when he was 3.

Related News
Articles
Obama to reverse limits on stem cell research
Following DNA map to new world of healing
When President Obama lifts the ban on funding embryonic stem-cell research Monday, he's delivering on his promise of hope for families like Amy Katz's whose children live with Type 1 diabetes.

"This is huge," said Katz, founder of Carnival for a Cure.

"This is a big step to getting funding to the people who will find a cure."

Katz, whose 10-year-old daughter, Remi, was diagnosed with Type 1 juvenile diabetes when she was 2, said she organized the first carnival four years ago to help fund promising research that couldn't get federal cash.

Sunday, families gathered at the annual children's fair - complete with clowns, carnival games and low-sugar treats - to raise money for the Diabetes Research Institute, which has been pursuing stem-cell research with private donations.

"This research needs and deserves federal funding," said Danielle Gregory, whose 6-year-old son, Leo, was diagnosed with diabetes at age 3.

Embryonic stem cells hold the promise of replicating the pancreatic cells that produce insulin.

Transplanted cells effectively cure Type 1 diabetics, but the current supply - from donated organs - cannot meet the need.

"There's a shortage of these cells for transplant," said Robert Pearlman, president of the Diabetes Research Institute Foundation, noting that 1.5 million Americans live with Type 1 diabetes, but only 6,000 donor pancreases are available each year.

Embryonic stem cells "will allow us to grow an unlimited supply," Pearlman said.

As Obama signs the executive order today reversing President George W. Bush's restrictions on stem-cell research, he is also expected to declare that science - not political ideology - will guide his administration.

"We've got eight years of science to make up for," said Dr. Curt Civin, whose research allowed scientists to isolate stem cells. "Now, the silly restrictions are lifted."

[e-mail]

With News Wire Services

[BullsEye]

Locked and loaded. Thanks Pizza

Which are you top watchers??

[DFLY]

VCII watch for interest on this one too.TINY float.

http://www.vivicells.com/

[PIZZABUSTER1]

ACTC-MCET COULD HAVE A NICE RIDE HERE AS WELL

[PIZZABUSTER1]

VODGE--- AND BCHC---

[ChartPoP]

PIZZABUSTER1~ What stem cell stock looks the best? tia

[PIZZABUSTER1]

sighned sealed and delivered -- now just add some ask slapping

[PIZZABUSTER1]

CHO CHO CHARLIE AND CHATANOOGA EXPRESS-- SHOW ME DA MONEY STEM CELLS

[DFLY]

agreed ride the stemmie trains choo choo!))

[PIZZABUSTER1]

DFLY== ACTC GETTING SOME LOVE--- UP 63%%%%%%%%%%% -- THEY GETTING JIGGY WITH IT

[PIZZABUSTER1]

WAIT THIS WHOLE FREAKING WEEK GOING TO BE MONSTEROUS --- GET URE AMMO READY

[BullsEye]

When is the Stem Cell Boom coming?

[PIZZABUSTER1]

MCET-NBS-SCLL-VODGE LOOK GREAT HERE

[DFLY]

indeed!)

wait til the $ really starts flowing into these companies when the govt funding and grants comes into play.) I guess go with the flow and see how long the buzz lasts at least.

[AMA]

Which ones?

[PIZZABUSTER1]

this news is huge for all stemmies---TIME TO DIP INTO THE SAVINGS

[DFLY]

Here we go folks Obama bout ta sign ITS OFFICIAL!!!!)STEMMIES may they be lifechanging for all involved!)

[sweet crude]

CEHC (.007) acquiring rev producing stem cell deal

The stem cell company is based in Tampa, FL, and has been treating patients for the last four years for such serious chronic diseases including ALS, Alzheimer's, Parkinsonism, multiple sclerosis, autism, post stroke, brain damage, diabetes, heart disease, advanced kidney disease, COPD, scleroderma, lupus, rheumatoid arthritis, Crohn's, advanced cancer, transverse myeltis, etc.

Financial Earnings

For fiscal year 2008, the Company posted total revenues of around $3 million (unaudited), and is currently profitable and cash flow positive.

Operation Centers

The Company currently treats patients in its Tampa, Florida facility for anti-aging medicine (bio-identical hormones, immunological, cardiac, pulmonary, and metabolic workups), as well as treatments involving autologous stem cells.

Internationally, the company operates, with Government approval, facilities in Mexico, and Lima, Peru. In these out of country locations patients are treated with specific organ stem cells extracted from umbilical cord blood for the serious diseases listed above. The Company is seeking to expand operations with new stem cell treatment centers around the world.

Umbilical Cord Stem Cells Treatment

The Company focuses on the use of umbilical cord stem cells in the treatment of a wide variety of disorders. The availability of umbilical cord blood makes this an appropriate source for stem cells. All donors are carefully screened to rule out HIV, Hepatitis B and C and a variety of other contagious conditions.

The stem cells are extracted from the umbilical cord blood and placed into culture for several weeks. During this time specific agents are added in the culture which will direct the stem cells to become early differentiated heart stem cells; pancreas stem cells that secrete insulin(for diabetes); pulmonary(lung) stem cells; kidney stem cells; neuron stem cells(for Parkinsonism, Alzheimer’s, Autism, Stroke, Brain Damage, spinal cord injury, multiple sclerosis); muscle stem cells; hematopoietic stem cells(for blood diseases).

These types of stem cells may also be incorporated and mixed with immunological cells such as T lymphocytes, T regulatory cells, T cytotoxic cells, Natural killer cells, anti-cytokines, anti-interleukins to treat autoimmune disorders such as rheumatoid arthritis, lupus, scleroderma and Crohn’s disease.

Adult Stem Cells Treatment

Adult stem cells are in every organ of our body; heart, brain, lung, kidney, pancreas, spinal cord, eyes, gastrointestinal tract. They are essential in repair of injured and diseased tissues. However, in various injuries and disease the extent of the problem is overwhelming and insufficient numbers of adult stem cells cannot correct the problem.

A new form of treatment that the Company offers is that of administration of the patient’s own stem cells back into their body. The patient’s own blood sample (or in some cases) a sample of their bone marrow is sent to our laboratory The laboratory extracts out adult stem cells from this sample and expands them into millions of cells. Approximately a week later these are then sent back to the patient’s physician for administration. Patients may also have this procedure done at one of their treatment centers in California or Florida.

The Company considers the procedure safe since it involves the use of the patient’s own stem cells so that there is no problem with engraftment or rejection. The procedure should be considered for any major serious medical disorder or injury; also as part of an anti-aging medicine regime.

Anti-Aging Division

The Company will also begin selling anti-aging oral products for prevention of cardiac disease, lung disorders, diabetes and neurodegenerative diseases such as ALS, multiple sclerosis, Parkinsonism and Alzheimer's as well as anti-aging skin creams. The company plans to submit for patenting its protocol for pancreatic stem cells that produce insulin and its neuron stem cells that secrete dopamine.

Example Patient Case Studies

Case#1: A 65 year old had a history of marked Diabeties (Type 1) that required him to take large doses of insulin, with blood sugars levels initially at 850. The patient received two treatments of pancreatic stem cells that produced insulin. Following the patients stem cell transplant his requirements are now minimal, and his blood sugar is now in the range of 74.

Case#2: A 44 year old male, spinal cord injury, received neuron stem cells and nerve growth factors at site of injury, and now undergoing intensive physical therapy rehabilitation with future use of trigger point electric stimulation and use of a fes bike, possible future candidate for sacral nerve bladder pacemaker.

http://www.ludlowcapital.com/reports/cehc.html

[DFLY]

HOLY stemmie runners..clockwork!

[DFLY]

GM all its ONNNNNNNNNNNNNNNNNNNNNNN!) 11:45 Est the Pres goin ta lift the ban!))

[xyz1002]

GERN, ATHX, ASTM, I'm in these 3. I've feeling ATHX will be the highest % gainer simply because of the low float. If you know how to trade-in and out you can make a lot of money. I can't do that so I'm holding them long term. By the end of 09 they will be much much higher.

The PK/OTC ones like cbai, actc, are good ones as well if you know when to get in and how to trade them but very risky. These company have a tendency to raise money by selling shares in this kind of situation.

all the best.

btw- Tomorrow will be the signing of first executive orders of quite a few to come. Stem cell as a sector will do well.

[uw86]

own these stocks but we knew this was coming; will be short-lived pop iomo

[PatD100]

What you talkin bout?

[DFLY]

Source: Obama to reverse limits on stem cell work


WASHINGTON – Reversing an eight-year-old limit on potentially life-saving science, President Barack Obama plans to lift restrictions Monday on taxpayer-funded research using embryonic stem cells.

The long-promised move will allow a rush of research aimed at one day better treating, if not curing, ailments from diabetes to paralysis — research that crosses partisan lines, backed by such notables as Nancy Reagan and the late Christopher Reeve. But it stirs intense controversy over whether government crosses a moral line with such research.

Obama will hold an event at the White House to announce the move, a senior administration official said Friday. The official spoke on condition of anonymity because the policy had not yet been publicly announced.

Embryonic stem cells are master cells that can morph into any cell of the body. Scientists hope to harness them so they can create replacement tissues to treat a variety of diseases — such as new insulin-producing cells for diabetics, cells that could help those with Parkinson's disease or maybe even Alzheimer's, or new nerve connections to restore movement after spinal injury.

"I feel vindicated after eight years of struggle, and I know it's going to energize my research team," said Dr. George Daley of the Harvard Stem Cell Institute and Children's Hospital of Boston, a leading stem cell researcher.

But the research is controversial because days-old embryos must be destroyed to obtain the cells. They typically are culled from fertility-clinic leftovers otherwise destined to be thrown away.

Under President George W. Bush, taxpayer money for that research was limited to a small number of stem cell lines that were created before Aug. 9, 2001, lines that in many cases had some drawbacks that limited their potential usability.

But hundreds more of such lines — groups of cells that can continue to propagate in lab dishes — have been created since then, ones that scientists say are healthier, better suited to creating treatments for people rather than doing basic laboratory science.

Work didn't stop. Indeed, it advanced enough that this summer, the private Geron Corp. will begin the world's first study of a treatment using human embryonic stem cells, in people who recently suffered a spinal cord injury.

Nor does Obama's change fund creation of new lines. But it means that scientists who until now have had to rely on private donations to work with these newer stem cell lines can apply for government money for the research, just like they do for studies of gene therapy or other treatment approaches.

The aim of the policy is to restore "scientific integrity" to the process, the administration official said.

"America's biomedical research enterprise experienced steady decline over the past eight years, with shrinking budgets and policies that elevated ideology over science. This slowed the pace of discovery and the search for cures," said Sean Morrison, director of the University of Michigan's Center for Stem Cell Biology.

Critics immediately denounced the move.

"Taxpayers should not have to foot the bill for experiments that require the destruction of human life," said Tony Perkins of the conservative Family Research Council. "President Obama's policy change is especially troubling given the significant adult stem cell advances that are being used to treat patients now without harming or destroying human embryos."

Indeed, there are different types of stem cells: So-called adult stem cells that produce a specific type of tissue; younger stem cells found floating in amniotic fluid or the placenta. Scientists even have learned to reprogram certain cells to behave like stem cells.

But even researchers who work with varying types consider embryonic stem cells the most flexible and thus most promising form — and say that science, not politics, should ultimately judge.

"Science works best and patients are served best by having all the tools at our disposal," Daley said.

Obama made it clear during the campaign he would overturn Bush's directive.

During the campaign, Obama said, "I strongly support expanding research on stem cells. I believe that the restrictions that President Bush has placed on funding of human embryonic stem cell research have handcuffed our scientists and hindered our ability to compete with other nations."

He said he would lift Bush's ban and "ensure that all research on stem cells is conducted ethically and with rigorous oversight."

"Patients and people who've been patient advocates are going to be really happy," said Amy Comstock Rick of the Coalition for the Advancement of Medical Research.

The ruling will bring one immediate change: As of Monday, scientists who've had to meticulously keep separate their federally funded research and their privately funded stem cell work — from buying separate microscopes to even setting up labs in different buildings — won't have that expensive hurdle anymore.

Next, scientists can start applying for research grants from the National Institutes of Health. The NIH already has begun writing guidelines that, among other things, are expected to demand that the cells being used were derived with proper informed consent from the woman or couple who donated the original embryo

[DFLY]

prolly all the big board stemmies STEM GERN NBS etc and most the otc stemmies even!))Its on now when lifted imo. May be the hottest sector for 09!